Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp (NASDAQ:TWST), filed a Form 4 on August 14, 2026, reporting a stock option exercise and subsequent sale of common shares on August 12, 2026, conducted under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Option exercised: Leproust exercised an employee stock option (transaction code M) for 19,952 shares of common stock at an exercise price of $26.66 per share on August 12, 2026.
  • Shares sold: 19,952 shares of common stock were disposed of (transaction code S) at a weighted average price of $125.0756 per share, with individual sale prices ranging from $125.00 to $125.25 per share.
  • Post-transaction ownership: Following the reported transactions, Leproust directly holds 818,938 shares of common stock.
  • 10b5-1 plan: According to the filing, both transactions were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Leproust on May 27, 2025.
  • Remaining options: Leproust retains derivative securities including options to purchase shares at exercise prices of $23.33, $67.85, $8.82, and $26.66, covering a combined 404,948 shares across four outstanding option grants.

Leproust Option Exercise and Share Sale Details at Twist Bioscience

According to the filing, Emily M. Leproust, who serves as both Chief Executive Officer and a Director of Twist Bioscience Corp, executed two linked transactions on August 12, 2026. She first exercised an employee stock option covering 19,952 shares at an exercise price of $26.66 per share, bringing her directly held common stock to 838,890 shares. She then sold those same 19,952 shares at a weighted average price of $125.0756 per share, reducing her direct holdings to 818,938 shares.

The filing discloses that sales occurred at prices ranging from $125.00 to $125.25 per share, and that full information on the number of shares sold at each specific price is available upon request to the SEC staff, the issuer, or a security holder. Both transactions were carried out under a Rule 10b5-1 trading plan that Leproust had adopted on May 27, 2025, according to the filing.

In Table II, the filing lists several remaining employee stock option grants held directly by Leproust. These include options with exercise prices of $23.33 (covering 131,290 shares), $67.85 (covering 64,950 shares), $8.82 (covering 75,439 shares), and the $26.66 option from which the 19,952 shares were exercised, with 133,269 shares remaining. An earlier option at $5.95 shows zero remaining shares. The filing was signed by Kendra Fox as Attorney-in-Fact for Emily M. Leproust and dated August 14, 2026.

What Was Disclosed

The filing reports Leproust's exercise of 19,952 stock options at $26.66 and same-day sale of those shares at a weighted average of $125.0756, both executed under a pre-adopted 10b5-1 plan, leaving her with 818,938 directly held shares.